Kinase Inhibitor class drugs

53 results

  • Afinitor

    (everolimus)
    Novartis Pharmaceuticals Corporation
    Usage: AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

  • Alecensa

    (ALECTINIB HYDROCHLORIDE)
    Genentech, Inc.
    Usage: ALECENSA is indicated for the adjuvant treatment of adult patients with resected ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adults with metastatic ALK-positive NSCLC, both confirmed by an FDA-approved test.

  • Aliqopa

    (copanlisib)
    Bayer HealthCare Pharmaceuticals Inc.
    Usage: ALIQOPA is indicated for adult patients with relapsed follicular lymphoma (FL) who have undergone at least two prior systemic therapies. Its accelerated approval is based on overall response rates, with continued approval dependent on further confirmation of clinical benefit.

  • Alunbrig

    (brigatinib)
    Takeda Pharmaceuticals America, Inc.
    Usage: ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) confirmed by an FDA-approved test.

  • Augtyro

    (repotrectinib)
    E.R. Squibb & Sons, L.L.C.
    Usage: AUGTYRO is indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for patients aged 12 and older with NTRK gene fusion-positive solid tumors that are advanced or metastatic, or where surgery poses severe risk, and have limited treatment options.

  • Ayvakit

    (avapritinib)
    Blueprint Medicines Corporation
    Usage: AYVAKIT® is indicated for adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM). It is not recommended for patients with platelet counts below 50 × 10⁹/L.

  • Balversa

    (Erdafitinib)
    Janssen Products LP
    Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with FGFR3 genetic alterations, following progression on at least one prior systemic therapy. Selection of patients must utilize an FDA-approved companion diagnostic. It is not recommended for those eligible for PD-1 or PD-L1 inhibitors.

  • Bosulif

    (Bosutinib)
    Pfizer Laboratories Div Pfizer Inc
    Usage: BOSULIF is indicated for treating chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in adults and pediatric patients (1 year and older), as well as for adult patients with accelerated or blast phase Ph+ CML who have resistance or intolerance to prior therapy.

  • Brukinsa

    (zanubrutinib)
    BEIGENE USA, INC.
    Usage: BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), relapsed or refractory marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed or refractory follicular lymphoma (FL) in combination with obinutuzumab.

  • Cabometyx

    (cabozantinib)
    Exelixis, Inc.
    Usage: CABOMETYX is indicated for advanced renal cell carcinoma (RCC), both as a monotherapy and in combination with nivolumab. It is also used for hepatocellular carcinoma (HCC) after sorafenib treatment and for locally advanced or metastatic differentiated thyroid cancer (DTC) in patients 12 and older who are radioactive iodine-refractory.